About James La Rossa

This author has not yet filled in any details.
So far James La Rossa has created 176 blog entries.

Johnson & Johnson gets FDA nod for twice-yearly schizophrenia drug, Invega Hafyera

By |2021-11-11T16:56:29-08:00September 1st, 2021|Brief Bulletins from the Field, We Know Psychiatry|

Johnson & Johnson thinks a longer-acting treatment against schizophrenia will help keep patients on their prescriptions and reduce their chances of a relapse. Now, with a FDA nod under its belt, the company is pushing Invega Hafyera as just the med to fit the bill. The FDA Wednesday approved J&J’s [...]

Placebo-controlled trial: The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain

By |2021-08-23T10:20:11-07:00August 23rd, 2021|Brief Bulletins from the Field, We Know Psychiatry|

Background Precise cannabis treatment dosing remains a major challenge, leading to physicians’ reluctance to prescribe medical cannabis. Objective To test the pharmacokinetics, analgesic effect, cognitive performance and safety effects of an innovative medical device that enables the delivery of inhaled therapeutic doses of Δ9-Tetrahydrocannabinol (THC) in patients with chronic pain. [...]

Check List for Suicide Risk is Validated

By |2021-11-11T16:56:43-08:00August 16th, 2021|Brief Bulletins from the Field, We Know Psychiatry|

The objective of this research was to develop and evaluate an evidence-based suicide attempt risk checklist [i.e., the Durham Risk Score (DRS)] to aid clinicians in the identification of individuals at risk for attempting suicide in the future. Methods and findings Three prospective cohort studies, including a population-based study from [...]

Biogen Withdrew Aduhelm Paper After JAMA Asked for Edits

By |2021-08-03T09:26:20-07:00August 3rd, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|

According to well-placed recent reports, Biogen Inc withdrew its paper that analyzed results from the clinical trials of its controversial Alzheimer's drug, Aduhelm, that was submitted to medical journal JAMA. Biogen withdrew the paper as JAMA considered rejecting it unless edits were made, according to the report. (https://bit.ly/3f2zsvf) The U.S. [...]

Some Teenagers At Risk Of Self-Harming Can Be Identified A Decade In Advance

By |2021-07-30T04:21:28-07:00July 30th, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|

There are multiple risk factors for self-harm, including a history of abuse, trauma, physical and mental illness, and bullying. Identifying these factors is a key part of prevention, ensuring that those at risk receive appropriate support as early as possible — but despite this, predicting who may end up engaging [...]

FDA Reviewers: Why We Are Against Approval of Aducanumab for Alzheimer’s

By |2021-05-06T09:35:36-07:00May 6th, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|

Three members of a US Food and Drug Administration (FDA) advisory committee are explaining why they do not support approval of the drug aducanumab (Biogen, Eisai) for the treatment of Alzheimer's disease (AD). G. Caleb Alexander, MD, Scott Emerson, MD, PhD, and Aaron Kesselheim, MD, JD, MPH, all serve on the [...]

Novel Drug Offers Rapid Relief From Agitation in Serious Mental Illness

By |2021-05-06T09:36:50-07:00May 6th, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|

An investigational, orally dissolving film formulation of dexmedetomidine (BXCL501, BioXcel Therapeutics) may offer rapid relief from acute agitation related to schizophrenia or bipolar disorder (BD), results of two phase 3, randomized, placebo-controlled trials show. Dr Leslie Citrome For both disorders, BXCL501 showed "superiority over placebo" by meeting the primary endpoint of reduction of agitation as [...]

Associations between breast cancer survivorship and adverse mental health outcomes: A matched population-based cohort study in the United Kingdom

By |2021-01-19T12:45:20-08:00January 19th, 2021|Brief Bulletins from the Field, We Know Psychiatry|

SUMMARY In this study, we observed that compared to women with no prior cancer, breast cancer survivors had higher risk of anxiety, depression, sleep problems, sexual dysfunction, fatigue, receipt of opioid analgesics, and pain. Relative risks estimates tended to decrease over time, but anxiety and depression were significantly increased for [...]

Go to Top